V V Kakkar1. Show Affiliations » 1. Thrombosis Research Institute, London, UK.
Abstract
Entities: Chemical Disease Species
Mesh： See more » Anticoagulants/adverse effectsAnticoagulants/economicsAnticoagulants/therapeutic useCost-Benefit AnalysisFibrinolytic Agents/adverse effectsFibrinolytic Agents/economicsFibrinolytic Agents/therapeutic useHeparin, Low-Molecular-Weight/adverse effectsHeparin, Low-Molecular-Weight/economicsHeparin, Low-Molecular-Weight/therapeutic useHumansPostoperative Complications/economicsPostoperative Complications/physiopathologyPostoperative Complications/prevention & controlPulmonary Embolism/economicsPulmonary Embolism/physiopathologyPulmonary Embolism/prevention & controlRisk FactorsThrombophlebitis/economicsThrombophlebitis/physiopathologyThrombophlebitis/prevention & control
Substances： See more » AnticoagulantsFibrinolytic AgentsHeparin, Low-Molecular-Weight
Year: 1997 PMID： 9399405
Source DB: PubMed Journal: Semin Hematol ISSN： 0037-1963 Impact factor: 3.851